Fmr LLC Decreases Stock Holdings in Smith & Nephew plc (NYSE:SNN)

FMR LLC reduced its stake in Smith & Nephew plc (NYSE:SNN - Free Report) by 4.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 427,106 shares of the medical equipment provider's stock after selling 21,131 shares during the quarter. FMR LLC owned about 0.10% of Smith & Nephew worth $13,300,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Argonautica Private Wealth Management Inc. increased its holdings in Smith & Nephew by 6.3% in the 2nd quarter. Argonautica Private Wealth Management Inc. now owns 10,244 shares of the medical equipment provider's stock worth $254,000 after buying an additional 605 shares during the period. First Trust Direct Indexing L.P. increased its holdings in Smith & Nephew by 6.9% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 9,659 shares of the medical equipment provider's stock worth $301,000 after buying an additional 626 shares during the period. Inspire Advisors LLC increased its holdings in Smith & Nephew by 3.0% in the 2nd quarter. Inspire Advisors LLC now owns 22,286 shares of the medical equipment provider's stock worth $552,000 after buying an additional 639 shares during the period. Rhumbline Advisers increased its holdings in Smith & Nephew by 8.6% in the 2nd quarter. Rhumbline Advisers now owns 10,365 shares of the medical equipment provider's stock worth $257,000 after buying an additional 819 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its holdings in Smith & Nephew by 5.6% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 17,218 shares of the medical equipment provider's stock worth $536,000 after buying an additional 920 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SNN has been the topic of several research reports. Deutsche Bank Aktiengesellschaft downgraded shares of Smith & Nephew from a "buy" rating to a "hold" rating in a report on Friday, November 1st. StockNews.com cut shares of Smith & Nephew from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Finally, Berenberg Bank cut shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Wednesday, November 6th.

Smith & Nephew Stock Performance

Shares of NYSE SNN traded down $0.18 during midday trading on Thursday, reaching $25.58. 583,733 shares of the stock were exchanged, compared to its average volume of 861,124. Smith & Nephew plc has a twelve month low of $23.65 and a twelve month high of $31.72. The firm has a 50-day simple moving average of $26.75 and a two-hundred day simple moving average of $27.89. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11.

Smith & Nephew Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.